中国干细胞、癌症免疫疗法第一股崩盘

tim1403

3 P; X! t' z, \6 q

+ C8 w% f1 z7 e( E中国干细胞、癌症免疫疗法第一股崩盘
7 H9 [+ J; m# g0 R8 F7 G2015-06-26
/ @9 m6 {! [! x/ b  q9 K/ _ 3 q% B! z1 Z, g1 ~8 X' Q+ x
Here's still a biotech investment lesson: be careful of Chinese fraudsters in biotech clothing.4 u) L# ?; `1 U6 K+ Q' l
$ Q7 f7 z+ B5 e# w' s# l

  S. Y: E( X7 Y0 o# w0 l( {On April 7, 2015, The Pump Stopper at Seeking Alpha released a bearish report claiming that Cellular Biomedicine (NASDAQ: CBMG) has achieved an unsustainable valuation with paid stock promotion. The company’s cell therapies are worthless and certain executives have questionable histories.
0 b9 I6 S' |# Y' \, }, H: V! x4 E2 n( I1 A/ b& f& P3 T2 ^
/ [' F. \$ e/ i
Cellular Biomedicine is a Chinese cell therapy stock which I stumbled upon when LifeTech Capital released an extremely bullish report with a target price of $32.50. I felt very strange, but I didn’t find any solid evidence against LifeTech Capital. Now it turned out to be a paid stock promotion.
+ X& K5 u' ~$ |4 T* A
- Y, A" t% w: s0 x6 z
& Y, R" Q3 L% ?$ u, PIn February 2015, Cellular Biomedicine acquired CAR-T therapies targeting CD19, CD20, CD30, and EGFR from the Chinese PLA General Hospital in a RMB12 million deal. It sounds too cheap to be true. Furthermore, the company’ R&D expense was much lower than G&A cost in the last two years (2014: $2.67 vs. $8.41 million; 2013: $1.89 vs. $9.31 million)., and EGFR from the Chinese PLA General Hospital in a RMB12 million deal. It sounds too cheap to be true. Furthermore, the company’ R&D expense was much lower than G&A cost in the last two years (2014: $2.67 vs. $8.41 million; 2013: $1.89 vs. $9.31 million).& z! [7 p6 j5 W

) p" H- N+ X0 }: r( W7 p4 T* t3 \* N- Z/ ^
I saw why four CAR-T therapies only cost RMB12 million when the Phase I results of CAR-CD19 came out on March 25, 2015. The trial enrolled nine adult patients with R/R B-cell ALL, only two had a complete response. One of those patients eventually died of graft-versus-host disease. The results were dim when compared to Juno Therapeutics’ (NASDAQ: JUNO) complete response rate of 90% presented at the ASH2014 Annual Meeting. only cost RMB12 million when the Phase I results of CAR-CD19 came out on March 25, 2015. The trial enrolled nine adult patients with R/R B-cell ALL, only two had a complete response. One of those patients eventually died of graft-versus-host disease. The results were dim when compared to Juno Therapeutics’ (NASDAQ: JUNO) complete response rate of 90% presented at the ASH2014 Annual Meeting.
9 w' l7 I/ v0 B4 Q, i' }2 J" |0 @: c5 o5 ?8 f/ q4 R

0 H) _2 o) w. Q/ {: b5 p  AHere's still a biotech investment lesson: be careful of Chinese fraudsters in biotech clothing.
1 E+ p/ y/ r7 ]2 H1 T

iytbxxg

Here's still a biotech investment lesson: be careful of Chinese fraudsters in biotech clothing.
. r, y7 X% Q4 O9 a% N* O) S好惭愧的语言呀% w/ z( v! z$ K! |3 }
这是哪个专家说的9 i. I  j9 l8 r  d. Y

tim1403

这里要告诉你的是投资生物科技类股的教训：小心在中国那些披上生物科技外衣的骗子！( y4 G* Z& R2 ^* [( I: p; Z: G

sunnyhuan0629

我想请教下，那在中国，现在那些天使投资人怎么去评估项目？或者国内真的有很好的原创技术的话，会吸引到国外的投资者么？并且生命科学领域的投资热看起来才刚刚起步不久，应该还会持续，怎么理智地去行动呢？

tim1403

目前国外的基金还不能投资细胞治疗产业，因为他是限制外商投资的项目之一